FREIENBACH, Switzerland--(BUSINESS WIRE)--January 12th 2014-- EffRx Pharmaceuticals SA today announced that it has received just over CHF 2.3 million in an equity round from a recent offering. All funds were raised through existing shareholders.
Christer Rosén, Chairman & CEO stated, “This is a strong supportive round of financing to assist EffRx to kick-off its first orphan drug clinical trial program as well as to start preparations for a planned IPO. We plan to shortly complement this internal financing with an external pre-IPO round to have the strongest possible position during the IPO process”.
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that develops novel therapeutic entities including orphan indications by applying its proprietary technology platform to well characterized molecules. EffRx developments focus at improving the quality of life of patients with unmet medical needs.
Contacts
EffRx Pharmaceuticals
Christen Rosén
+1-561-308-7780
crosen@effrx.com
